ArticleBrain informatics2026
A deep-learning framework for brain tumor segmentation via three-dimensional mass-preserving geometric transformation.
Article in Brain informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article presents a robust and efficient framework for brain tumor segmentation based on deep learning. We introduce a novel three-dimensional (3D) mass-preserving geometric transformation (MPGT) that employs a homotopy method to transform irregular brain magnetic resonance (MR) images into standardized solid cubes. This transformation preserves local mass ratios while maintaining global structural integrity, providing a structured input for deep learning models. Furthermore, we propose a modified two-phase segmentation strategy to minimize inference time and a postprocessing technique to enhance lesion-wise performance. Extensive validation on the Brain Tumor Segmentation (BraTS) Challenge 2023 dataset demonstrates that our method, when integrated with nnU-Net, achieves competitive Dice scores of 0.9282 (Whole Tumor), 0.8812 (Tumor Core), and 0.8527 (Enhanced Tumor). These results are superior to or comparable with top-ranking competition entries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.